organophosphonates has been researched along with Cerebrovascular Disorders in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dirnagl, U; Huth, A; Jacobsen, P; McDonald, F; Neuhaus, R; Ottow, E; Schneider, HH; Sheardown, M; Turski, L; Wiegand, F | 1 |
Fischer, KC; McKusick, KA; Pendergrass, HP; Potsain, MS | 1 |
2 other study(ies) available for organophosphonates and Cerebrovascular Disorders
Article | Year |
---|---|
ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cells, Cultured; Cerebrovascular Disorders; Craniocerebral Trauma; Evoked Potentials; Excitatory Amino Acid Antagonists; Gerbillinae; In Vitro Techniques; Mice; Neuroprotective Agents; Organophosphonates; Quinoxalines; Radioligand Assay; Rats | 1998 |
Improved brain scan specificity utilizing 99mTc-pertechnetate and 99mTc(Sn)-diphosphonate.
Topics: Adult; Aged; Astrocytoma; Brain; Brain Abscess; Brain Diseases; Brain Neoplasms; Cerebrovascular Disorders; Female; Hematoma, Subdural; Humans; Male; Middle Aged; Organophosphonates; Radionuclide Imaging; Technetium | 1975 |